Tradestie Institutional Equity Comparison Engine

CVM vs CRIS โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

CVM Overall Edge

CVM Captures Institutional Edge (3โ€“1 Pillars ยท 8โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Cel-Sci Corporation (CVM) driven by superior Valuation, Growth & Margin, Momentum & Technical while CRIS counters with relative strength in Options & Structure. Fundamentally, CVM trades at 23.0x Forward P/E with 0.0% operating margin (-62.7% YoY revenue) versus CRIS at N/M Forward P/E and -833.4% operating margin (-66.0% YoY). In options structure, CVM sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro) against CRIS sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner CVM
CVM 23.0x vs CRIS N/M Fwd P/E
Growth & Margin Winner CVM
Op Margin 0.0% vs -833.4% ยท YoY -62.7% vs -66.0%
Momentum & Technical Winner CVM
1Y -77.5% vs -61.0% ยท 52W Pos 10% vs 4%
Options & Structure Winner CRIS
BREAKDOWN (N/A IV) vs UNCLASSIFIED (N/A IV)
CVM NYSE American
Cel-Sci Corporation
Biological Products, (No Disgnostic Substances)
$1.59
+24.22% 1D
Market Cap $20.9M
1M Return -11.17%
1Y Return -77.48%
Forward P/E 23.0x
Unified AI Score
56.6 / 100 HOLD
Tech 60.0 Fund 54.0 Flow 50.0 Mom 60.0
CRIS NASDAQ
Curis Inc
Biological Products, (No Disgnostic Substances)
$0.44
-1.07% 1D
Market Cap $3.8M
1M Return +8.14%
1Y Return -61.04%
Forward P/E N/M
Unified AI Score
38.7 / 100 SELL
Tech 15.0 Fund 41.0 Flow 50.0 Mom 64.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: CVM -77.48% CRIS -61.04% Spread: +9.08 pp (CRIS Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period CVM Revenue CRIS Revenue CVM Op. Margin CRIS Op. Margin Margin Edge
FY2018 N/A $10M N/A -281.3% CRIS
FY2019 N/A $10M N/A -243.5% CRIS
FY2020 N/A $10M N/A -229.8% CRIS
FY2021 N/A $10M N/A -395.0% CRIS
FY2022 N/A $10M N/A -521.7% CRIS
FY2023 N/A $10M N/A -482.2% CRIS
FY2024 N/A $10M N/A -408.3% CRIS
FY2025 N/A $10M N/A -60.5% CRIS

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: CVM (8) vs CRIS (1)
Institutional Metric CVM CRIS Criterion Row Winner
Market Capitalization Scale $20.9M $3.8M Larger Scale CVM
Trailing P/E Ratio Valuation 23.0x 0.4x Lower Multiple CRIS
Forward P/E Ratio Valuation 23.0x N/M Lower Multiple CVM
Revenue Growth (YoY) Growth -62.7% -66.0% Higher Growth CVM
Operating Margin (TTM) Profitability 0.0% -833.4% Higher Margin CVM
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -252.5% -693.9% Higher ROE CVM
52-Week Range Position Momentum 10% ($1โ€“$8) 4% ($0โ€“$7) Stronger Trend CVM
Beta / 30D Volatility Risk Regime 0.65ฮฒ ยท 120% Vol 11.40ฮฒ ยท 269% Vol Lower Realized Risk CVM
Unified Institutional Score Composite Signal 56.6 / 100 (HOLD) 38.7 / 100 (SELL) Higher Composite CVM

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full CVM vs CRIS Buy Guide
CVM BREAKDOWN
29d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live CVM Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CRIS UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live CRIS Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither CVM nor CRIS registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.